{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:39:06Z","timestamp":1761892746682},"reference-count":186,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.2337\/diacare.29.02.06.dc05-1267","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T22:41:57Z","timestamp":1147300917000},"page":"435-449","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":82,"title":["Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1"],"prefix":"10.2337","volume":"29","author":[{"given":"Matthew C.","family":"Riddle","sequence":"first","affiliation":[{"name":"Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031217403281600_R1","doi-asserted-by":"crossref","unstructured":"Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care\u200826: 2929\u20132940, 2003","DOI":"10.2337\/diacare.26.10.2929"},{"key":"2022031217403281600_R2","doi-asserted-by":"crossref","unstructured":"Deacon CF: Therapeutic strategies based on glucagon-like peptide 1. Diabetes\u200853:2181\u20132189, 2004","DOI":"10.2337\/diabetes.53.9.2181"},{"key":"2022031217403281600_R3","doi-asserted-by":"crossref","unstructured":"Vilsboll T, Holst JJ: Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia\u200847:357\u2013366, 2004","DOI":"10.1007\/s00125-004-1342-6"},{"key":"2022031217403281600_R4","doi-asserted-by":"crossref","unstructured":"Schmitz O, Brock B, Rungby J: Amylin agonists: a novel approach in the treatment of diabetes. Diabetes\u200853(Suppl. 3):S233\u2013S238, 2004","DOI":"10.2337\/diabetes.53.suppl_3.S233"},{"key":"2022031217403281600_R5","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Standards of medical care in diabetes. Diabetes Care\u200828(Suppl. 1):S4\u2013S35, 2005 [erratum in Diabetes Care\u200828:990, 2005]","DOI":"10.2337\/diacare.28.suppl_1.S4"},{"key":"2022031217403281600_R6","doi-asserted-by":"crossref","unstructured":"American Association of Clinical Endocrinologists: Consensus statement on guidelines for glycemic control. Endocrine Practice\u20088(Suppl. 1):5\u201311, 2002","DOI":"10.4158\/EP.8.S1.5"},{"key":"2022031217403281600_R7","doi-asserted-by":"crossref","unstructured":"A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group. Diabet Med\u200816:716\u2013730, 1999","DOI":"10.1046\/j.1464-5491.1999.00166.x"},{"key":"2022031217403281600_R8","doi-asserted-by":"crossref","unstructured":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med\u2008329:977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031217403281600_R9","unstructured":"Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl 2.):B21\u2013B29, 2000"},{"key":"2022031217403281600_R10","doi-asserted-by":"crossref","unstructured":"Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care\u200826:3080\u20133086, 2003","DOI":"10.2337\/diacare.26.11.3080"},{"key":"2022031217403281600_R11","doi-asserted-by":"crossref","unstructured":"Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA\u2008291:335\u2013342, 2004","DOI":"10.1001\/jama.291.3.335"},{"key":"2022031217403281600_R12","doi-asserted-by":"crossref","unstructured":"Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care\u200827:1535\u20131540, 2004","DOI":"10.2337\/diacare.27.7.1535"},{"key":"2022031217403281600_R13","doi-asserted-by":"crossref","unstructured":"Lebovitz HE: alpha-Glucosidase inhibitors. Endocrinol Metab Clin North Am\u200826:539\u2013551, 1997","DOI":"10.1016\/S0889-8529(05)70266-8"},{"key":"2022031217403281600_R14","doi-asserted-by":"crossref","unstructured":"van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: \u03b1-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care\u200828:154\u2013163, 2005","DOI":"10.2337\/diacare.28.1.154"},{"key":"2022031217403281600_R15","doi-asserted-by":"crossref","unstructured":"Goke B, Herrmann C, Goke R, Fehmann HC, Berghofer P, Richter G, Arnold R: Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest\u200824(Suppl. 3):25\u201330, 1994","DOI":"10.1111\/j.1365-2362.1994.tb02252.x"},{"key":"2022031217403281600_R16","doi-asserted-by":"crossref","unstructured":"Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W: Glucagon-like peptide 1 (7\u201336 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol\u200830:892\u2013896, 1995","DOI":"10.3109\/00365529509101597"},{"key":"2022031217403281600_R17","doi-asserted-by":"crossref","unstructured":"Schmitz O, Lund S, Andersen PH, Jonler M, Porksen N: Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care\u200825:342\u2013346, 2002","DOI":"10.2337\/diacare.25.2.342"},{"key":"2022031217403281600_R18","doi-asserted-by":"crossref","unstructured":"Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care\u200824:983\u2013988, 2001","DOI":"10.2337\/diacare.24.6.983"},{"key":"2022031217403281600_R19","doi-asserted-by":"crossref","unstructured":"Carroll MF, Izard A, Riboni K, Burge MR, Schade DS: Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care\u200825:2147\u20132152, 2002","DOI":"10.2337\/diacare.25.12.2147"},{"key":"2022031217403281600_R20","doi-asserted-by":"crossref","unstructured":"Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS: Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. J Clin Endocrinol Metab\u200888:5248\u20135254, 2003","DOI":"10.1210\/jc.2003-030649"},{"key":"2022031217403281600_R21","doi-asserted-by":"crossref","unstructured":"Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus: Multicenter Insulin Lispro Study Group. Arch Intern Med\u2008157:1249\u20131255, 1997","DOI":"10.1001\/archinte.157.11.1249"},{"key":"2022031217403281600_R22","doi-asserted-by":"crossref","unstructured":"Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care\u200826:881\u2013885, 2003","DOI":"10.2337\/diacare.26.3.881"},{"key":"2022031217403281600_R23","doi-asserted-by":"crossref","unstructured":"Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes\u200854:1\u20137, 2005","DOI":"10.2337\/diabetes.54.1.1"},{"key":"2022031217403281600_R24","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes\u200846:271\u2013286, 1997","DOI":"10.2337\/diabetes.46.2.271"},{"key":"2022031217403281600_R25","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031217403281600_R26","doi-asserted-by":"crossref","unstructured":"Cryer PE: Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev\u200815:42\u201346, 1999","DOI":"10.1002\/(SICI)1520-7560(199901\/02)15:1<42::AID-DMRR1>3.0.CO;2-B"},{"key":"2022031217403281600_R27","doi-asserted-by":"crossref","unstructured":"Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care\u200824:1711\u20131721, 2001","DOI":"10.2337\/diacare.24.10.1711"},{"key":"2022031217403281600_R28","doi-asserted-by":"crossref","unstructured":"Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT: Diabetes Control and Complications Trial. JAMA\u2008280:140\u2013146, 1998","DOI":"10.1001\/jama.280.2.140"},{"key":"2022031217403281600_R29","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet\u2008352:854\u2013865, 1998","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2022031217403281600_R30","doi-asserted-by":"crossref","unstructured":"Yki-Jarvinen H: Thiazolidinediones. N Engl J Med\u2008351:1106\u20131118, 2004","DOI":"10.1056\/NEJMra041001"},{"key":"2022031217403281600_R31","doi-asserted-by":"crossref","unstructured":"Vasudevan AR, Balasubramanyam A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther\u20086:850\u2013863, 2004","DOI":"10.1089\/dia.2004.6.850"},{"key":"2022031217403281600_R32","doi-asserted-by":"crossref","unstructured":"Lindstrom T, Eriksson P, Olsson AG, Arnqvist HJ: Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care\u200817:719\u2013721, 1994","DOI":"10.2337\/diacare.17.7.719"},{"key":"2022031217403281600_R33","doi-asserted-by":"crossref","unstructured":"Strowig SM, Aviles-Santa ML, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care\u200825:1691\u20131698, 2002","DOI":"10.2337\/diacare.25.10.1691"},{"key":"2022031217403281600_R34","doi-asserted-by":"crossref","unstructured":"Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD: Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care\u200825:2133\u20132140, 2002","DOI":"10.2337\/diacare.25.12.2133"},{"key":"2022031217403281600_R35","doi-asserted-by":"crossref","unstructured":"Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance: Seminars in Medicine of the Beth Israel Hospital, Boston. N Engl J Med\u2008334:777\u2013783, 1996","DOI":"10.1056\/NEJM199603213341207"},{"key":"2022031217403281600_R36","doi-asserted-by":"crossref","unstructured":"DeFronzo RA: Lilly Lecture 1987: The triumvirate: \u03b2-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes\u200837:667\u2013687, 1988","DOI":"10.2337\/diab.37.6.667"},{"key":"2022031217403281600_R37","doi-asserted-by":"crossref","unstructured":"Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD: Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes\u200847:523\u2013529, 1998","DOI":"10.2337\/diabetes.47.4.523"},{"key":"2022031217403281600_R38","doi-asserted-by":"crossref","unstructured":"Cherrington AD: Banting Lecture 1997: Control of glucose uptake and release by the liver in vivo. Diabetes\u200848:1198\u20131214, 1999","DOI":"10.2337\/diabetes.48.5.1198"},{"key":"2022031217403281600_R39","doi-asserted-by":"crossref","unstructured":"Consoli A: Role of liver in pathophysiology of NIDDM. Diabetes Care\u200815:430\u2013441, 1992","DOI":"10.2337\/diacare.15.3.430"},{"key":"2022031217403281600_R40","doi-asserted-by":"crossref","unstructured":"Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol\u2008240:E630\u2013E639, 1981","DOI":"10.1152\/ajpendo.1981.240.6.E630"},{"key":"2022031217403281600_R41","doi-asserted-by":"crossref","unstructured":"Rebrin K, Steil GM, Getty L, Bergman RN: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes\u200844:1038\u20131045, 1995","DOI":"10.2337\/diab.44.9.1038"},{"key":"2022031217403281600_R42","doi-asserted-by":"crossref","unstructured":"Lewis GF, Zinman B, Groenewoud Y, Vranic M, Giacca A: Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes\u200845:454\u2013462, 1996","DOI":"10.2337\/diabetes.45.4.454"},{"key":"2022031217403281600_R43","doi-asserted-by":"crossref","unstructured":"Myers SR, Diamond MP, Adkins-Marshall BA, Williams PE, Stinsen R, Cherrington AD: Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. Metabolism\u200840:66\u201371, 1991","DOI":"10.1016\/0026-0495(91)90194-2"},{"key":"2022031217403281600_R44","doi-asserted-by":"crossref","unstructured":"Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. Am J Physiol\u2008284:E671\u2013E678, 2003","DOI":"10.1152\/ajpendo.00492.2002"},{"key":"2022031217403281600_R45","doi-asserted-by":"crossref","unstructured":"Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med\u2008327:707\u2013713, 1992","DOI":"10.1056\/NEJM199209033271007"},{"key":"2022031217403281600_R46","doi-asserted-by":"crossref","unstructured":"Basu A, Shah P, Nielsen M, Basu R, Rizza RA: Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. J Investig Med\u200852:366\u2013374, 2004","DOI":"10.1136\/jim-52-06-30"},{"key":"2022031217403281600_R47","doi-asserted-by":"crossref","unstructured":"Caumo A, Luzi L: First-phase insulin secretion: does it exist in real life? Considerations on shape and function. Am J Physiol\u2008287:E371\u2013E385, 2004","DOI":"10.1152\/ajpendo.00139.2003"},{"key":"2022031217403281600_R48","doi-asserted-by":"crossref","unstructured":"Polonsky KS, Given BD, Van Cauter E: Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest\u200881:442\u2013448, 1988","DOI":"10.1172\/JCI113339"},{"key":"2022031217403281600_R49","doi-asserted-by":"crossref","unstructured":"Loew ER, Gray JS, Ivy AC: Is a duodenal hormone involved in carbohydrate metabolism? Am J Physiol\u2008270:659\u2013663, 1940","DOI":"10.1152\/ajplegacy.1940.129.3.659"},{"key":"2022031217403281600_R50","doi-asserted-by":"crossref","unstructured":"Elrick H, Stimmler L, Hlad CJ, Arai Y: Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab\u200824:1076\u20131082, 1964","DOI":"10.1210\/jcem-24-10-1076"},{"key":"2022031217403281600_R51","doi-asserted-by":"crossref","unstructured":"McIntyre N, Holdsworth CD, Turner DS: Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab\u200825:1317\u20131324, 1965","DOI":"10.1210\/jcem-25-10-1317"},{"key":"2022031217403281600_R52","doi-asserted-by":"crossref","unstructured":"Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest\u200846:1954\u20131962, 1967","DOI":"10.1172\/JCI105685"},{"key":"2022031217403281600_R53","doi-asserted-by":"crossref","unstructured":"Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab\u200863:492\u2013498, 1986","DOI":"10.1210\/jcem-63-2-492"},{"key":"2022031217403281600_R54","doi-asserted-by":"crossref","unstructured":"Muller WA, Faloona GR, Aguilar-Parada E, Unger RH: Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med\u2008283:109\u2013115, 1970","DOI":"10.1056\/NEJM197007162830301"},{"key":"2022031217403281600_R55","doi-asserted-by":"crossref","unstructured":"Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J: Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes\u200839:1381\u20131390, 1990","DOI":"10.2337\/diab.39.11.1381"},{"key":"2022031217403281600_R56","doi-asserted-by":"crossref","unstructured":"Butler PC, Rizza RA: Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes\u200840:73\u201381, 1991","DOI":"10.2337\/diabetes.40.1.73"},{"key":"2022031217403281600_R57","doi-asserted-by":"crossref","unstructured":"Unger RH: Glucagon physiology and pathophysiology in the light of new advances. Diabetologia\u200828:574\u2013578, 1985","DOI":"10.1007\/BF00281991"},{"key":"2022031217403281600_R58","doi-asserted-by":"crossref","unstructured":"Woods SC, Porte D Jr: Neural control of the endocrine pancreas. Physiol Rev\u200854:596\u2013619, 1974","DOI":"10.1152\/physrev.1974.54.3.596"},{"key":"2022031217403281600_R59","doi-asserted-by":"crossref","unstructured":"Ahren B: Autonomic regulation of islet hormone secretion: implications for health and disease. Diabetologia\u200843:393\u2013410, 2000","DOI":"10.1007\/s001250051322"},{"key":"2022031217403281600_R60","doi-asserted-by":"crossref","unstructured":"Ahren B, Holst JJ: The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes\u200850:1030\u20131038, 2001","DOI":"10.2337\/diabetes.50.5.1030"},{"key":"2022031217403281600_R61","doi-asserted-by":"crossref","unstructured":"Sacca L, Hendler R, Sherwin RS: Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones. J Clin Endocrinol Metab\u200847:1160\u20131163, 1978","DOI":"10.1210\/jcem-47-5-1160"},{"key":"2022031217403281600_R62","doi-asserted-by":"crossref","unstructured":"Bell PM, Firth RG, Rizza RA: Effects of hyperglycemia on glucose production and utilization in humans: measurement with [23H]-, [33H]-, and [614C]glucose. Diabetes\u200835:642\u2013648, 1986","DOI":"10.2337\/diabetes.35.6.642"},{"key":"2022031217403281600_R63","doi-asserted-by":"crossref","unstructured":"Adkins-Marshall B, Pagliassotti MJ, Asher JR, Connolly CC, Neal DW, Williams PE, Myers SR, Hendrick GK, Adkins RB Jr, Cherrington AD: Role of hepatic nerves in response of liver to intraportal glucose delivery in dogs. Am J Physiol\u2008262:E679\u2013E686, 1992","DOI":"10.1152\/ajpendo.1992.262.5.E679"},{"key":"2022031217403281600_R64","doi-asserted-by":"crossref","unstructured":"Moore MC, Connolly CC, Cherrington AD: Autoregulation of hepatic glucose production. Eur J Endocrinol\u2008138:240\u2013248, 1998","DOI":"10.1530\/eje.0.1380240"},{"key":"2022031217403281600_R65","doi-asserted-by":"crossref","unstructured":"Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care\u200824:371\u2013381, 2001","DOI":"10.2337\/diacare.24.2.371"},{"key":"2022031217403281600_R66","doi-asserted-by":"crossref","unstructured":"Horowitz M, Edelbroek MA, Wishart JM, Straathof JW: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia\u200836:857\u2013862, 1993","DOI":"10.1007\/BF00400362"},{"key":"2022031217403281600_R67","doi-asserted-by":"crossref","unstructured":"Pfeifer MA, Halter JB, Porte D Jr: Insulin secretion in diabetes mellitus. Am J Med\u200870:579\u2013588, 1981","DOI":"10.1016\/0002-9343(81)90579-9"},{"key":"2022031217403281600_R68","doi-asserted-by":"crossref","unstructured":"Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D: Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest\u200874:1318\u20131328, 1984","DOI":"10.1172\/JCI111542"},{"key":"2022031217403281600_R69","doi-asserted-by":"crossref","unstructured":"Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia\u200829:46\u201352, 1986","DOI":"10.1007\/BF02427280"},{"key":"2022031217403281600_R70","doi-asserted-by":"crossref","unstructured":"Greenbaum CJ, Prigeon RL, D\u2019Alessio DA: Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes\u200851:951\u2013957, 2002","DOI":"10.2337\/diabetes.51.4.951"},{"key":"2022031217403281600_R71","doi-asserted-by":"crossref","unstructured":"Lefebvre PJ, Luyckx AS: Glucagon and diabetes: a reappraisal. Diabetologia\u200816:347\u2013354, 1979","DOI":"10.1007\/BF01223153"},{"key":"2022031217403281600_R72","doi-asserted-by":"crossref","unstructured":"Unger RH, Orci L: The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet\u20081:14\u201316, 1975","DOI":"10.1016\/S0140-6736(75)92375-2"},{"key":"2022031217403281600_R73","doi-asserted-by":"crossref","unstructured":"Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA: Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus: role of hepatic and extrahepatic tissues. J Clin Invest\u200877:1525\u20131532, 1986","DOI":"10.1172\/JCI112467"},{"key":"2022031217403281600_R74","doi-asserted-by":"crossref","unstructured":"Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L: Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest\u2008102:744\u2013753, 1998","DOI":"10.1172\/JCI2720"},{"key":"2022031217403281600_R75","doi-asserted-by":"crossref","unstructured":"Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, Rizza RA: Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes\u200846:421\u2013432, 1997","DOI":"10.2337\/diabetes.46.3.421"},{"key":"2022031217403281600_R76","doi-asserted-by":"crossref","unstructured":"Phillips WT, Schwartz JG, McMahan CA: Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl J Med\u2008324:130\u2013131, 1991","DOI":"10.1056\/NEJM199101103240217"},{"key":"2022031217403281600_R77","doi-asserted-by":"crossref","unstructured":"Unger RH: Glucagon physiology and pathophysiology. N Engl J Med\u2008285:443\u2013449, 1971","DOI":"10.1056\/NEJM197108192850806"},{"key":"2022031217403281600_R78","doi-asserted-by":"crossref","unstructured":"Raskin P, Aydin I, Yamamoto T, Unger RH: Abnormal alpha cell function in human diabetes: the response to oral protein. Am J Med\u200864:988\u2013997, 1978","DOI":"10.1016\/0002-9343(78)90454-0"},{"key":"2022031217403281600_R79","doi-asserted-by":"crossref","unstructured":"Raskin P, Aydin I, Unger RH: Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes\u200825:227\u2013229, 1976","DOI":"10.2337\/diabetes.25.3.227"},{"key":"2022031217403281600_R80","doi-asserted-by":"crossref","unstructured":"Cooper GJS: Amylin compared with calcitonin gene-related peptide: structure, biology and relevance to metabolic disease. Endocr Rev\u200815:163\u2013201, 1994","DOI":"10.1210\/edrv-15-2-163"},{"key":"2022031217403281600_R81","doi-asserted-by":"crossref","unstructured":"Muff R, Born W, Fischer JA: Adrenomedullin and related peptides: receptors and accessory proteins. Peptides\u200822:1765\u20131772, 2001","DOI":"10.1016\/S0196-9781(01)00515-0"},{"key":"2022031217403281600_R82","doi-asserted-by":"crossref","unstructured":"Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM: Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem\u2008278:3293\u20133297, 2003","DOI":"10.1074\/jbc.C200629200"},{"key":"2022031217403281600_R83","doi-asserted-by":"crossref","unstructured":"Hay DL, Christopoulos G, Christopoulos A, Sexton PM: Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans\u200832:865\u2013867, 2004","DOI":"10.1042\/BST0320865"},{"key":"2022031217403281600_R84","doi-asserted-by":"crossref","unstructured":"Martinez A, Kapas S, Miller MJ, Ward Y, Cuttitta F: Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells. Endocrinology\u2008141:406\u2013411, 2000","DOI":"10.1210\/endo.141.1.7261"},{"key":"2022031217403281600_R85","doi-asserted-by":"crossref","unstructured":"Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J: Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. Am J Physiol\u2008276:E19\u2013E24, 1999","DOI":"10.1152\/ajpendo.1999.276.1.E19"},{"key":"2022031217403281600_R86","doi-asserted-by":"crossref","unstructured":"Mather KJ, Paradisi G, Leaming R, Hook G, Steinberg HO, Fineberg N, Hanley R, Baron AD: Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev\u200818:118\u2013126, 2002","DOI":"10.1002\/dmrr.263"},{"key":"2022031217403281600_R87","doi-asserted-by":"crossref","unstructured":"Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC: Amylin: a novel action in the brain to reduce body weight. Endocrinology\u2008141:850\u2013853, 2000","DOI":"10.1210\/endo.141.2.7378"},{"key":"2022031217403281600_R88","doi-asserted-by":"crossref","unstructured":"Rushing PA: Central amylin signaling and the regulation of energy homeostasis. Curr Pharm Des\u20089:819\u2013825, 2003","DOI":"10.2174\/1381612033455387"},{"key":"2022031217403281600_R89","doi-asserted-by":"crossref","unstructured":"Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D\u2019Alessio DA, Air EL, Woods SC: Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology\u2008142:5035, 2001","DOI":"10.1210\/endo.142.11.8593"},{"key":"2022031217403281600_R90","doi-asserted-by":"crossref","unstructured":"Mulder H, Gebre-Medhin S, Betsholtz C, Sundler F, Ahren B: Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. Am J Physiol\u2008278:E684\u2013E691, 2000","DOI":"10.1152\/ajpendo.2000.278.4.E684"},{"key":"2022031217403281600_R91","doi-asserted-by":"crossref","unstructured":"Mollet A, Meier S, Grabler V, Gilg S, Scharrer E, Lutz TA: Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin. Peptides\u200824:91\u201398, 2003","DOI":"10.1016\/S0196-9781(02)00280-2"},{"key":"2022031217403281600_R92","doi-asserted-by":"crossref","unstructured":"Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G: Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol\u2008164:509\u2013514, 2004","DOI":"10.1083\/jcb.200312135"},{"key":"2022031217403281600_R93","doi-asserted-by":"crossref","unstructured":"Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem\u2008214:829\u2013835, 1993","DOI":"10.1111\/j.1432-1033.1993.tb17986.x"},{"key":"2022031217403281600_R94","doi-asserted-by":"crossref","unstructured":"Dupre J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab\u200837:826\u2013828, 1973","DOI":"10.1210\/jcem-37-5-826"},{"key":"2022031217403281600_R95","doi-asserted-by":"crossref","unstructured":"Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ: International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev\u200855:167\u2013194, 2003","DOI":"10.1124\/pr.55.1.6"},{"key":"2022031217403281600_R96","doi-asserted-by":"crossref","unstructured":"Tseng CC, Zhang XY, Wolfe MM: Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am J Physiol\u2008276:E1049\u2013E1054, 1999","DOI":"10.1152\/ajpendo.1999.276.6.E1049"},{"key":"2022031217403281600_R97","doi-asserted-by":"crossref","unstructured":"Baggio L, Kieffer TJ, Drucker DJ: GLP-1 but not GIP regulates fasting and non-enteral glucose clearance in mice. Endocrinology\u2008141:3703\u20133709, 2000","DOI":"10.1210\/endo.141.10.7720"},{"key":"2022031217403281600_R98","doi-asserted-by":"crossref","unstructured":"Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y: Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A\u200896:14843\u201314847, 1999","DOI":"10.1073\/pnas.96.26.14843"},{"key":"2022031217403281600_R99","doi-asserted-by":"crossref","unstructured":"Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med\u20088:738\u2013742, 2002","DOI":"10.1038\/nm727"},{"key":"2022031217403281600_R100","doi-asserted-by":"crossref","unstructured":"Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O\u2019Harte FP, Flatt PR: Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes\u200854:2436\u20132446, 2005","DOI":"10.2337\/diabetes.54.8.2436"},{"key":"2022031217403281600_R101","doi-asserted-by":"crossref","unstructured":"Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest\u200891:301\u2013307, 1993","DOI":"10.1172\/JCI116186"},{"key":"2022031217403281600_R102","doi-asserted-by":"crossref","unstructured":"Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA: Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes\u200853\u2008(Suppl. 3):S220\u2013S224, 2004","DOI":"10.2337\/diabetes.53.suppl_3.S220"},{"key":"2022031217403281600_R103","doi-asserted-by":"crossref","unstructured":"Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes\u200850:1004\u20131011, 2001","DOI":"10.2337\/diabetes.50.5.1004"},{"key":"2022031217403281600_R104","doi-asserted-by":"crossref","unstructured":"Dube PE, Brubaker PL: Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res\u200836:755\u2013760, 2004","DOI":"10.1055\/s-2004-826159"},{"key":"2022031217403281600_R105","doi-asserted-by":"crossref","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes\u200844:1126\u20131131, 1995","DOI":"10.2337\/diabetes.44.9.1126"},{"key":"2022031217403281600_R106","doi-asserted-by":"crossref","unstructured":"Orskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagon-like peptide-1 7\u201336 amide and glucagon-like peptide-1 7\u201337 in healthy subjects are indistinguishable. Diabetes\u200842:658\u2013661, 1993","DOI":"10.2337\/diabetes.42.5.658"},{"key":"2022031217403281600_R107","doi-asserted-by":"crossref","unstructured":"Vahl TP, Paty BW, Fuller BD, Prigeon RL, D\u2019Alessio DA: Effects of GLP-1-(7\u201336)NH(2), GLP-1-(7\u201337), and GLP-1- (9\u201336)NH(2) on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab\u200888:1772\u20131779, 2003","DOI":"10.1210\/jc.2002-021479"},{"key":"2022031217403281600_R108","doi-asserted-by":"crossref","unstructured":"Turton MD, O\u2019Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature\u2008379:69\u201372, 1996","DOI":"10.1038\/379069a0"},{"key":"2022031217403281600_R109","doi-asserted-by":"crossref","unstructured":"Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes\u200848:1026\u20131034, 1999","DOI":"10.2337\/diabetes.48.5.1026"},{"key":"2022031217403281600_R110","doi-asserted-by":"crossref","unstructured":"Baggio LL, Huang Q, Brown TJ, Drucker DJ: A recombinant human glucagon-like peptide (GLP)-1 albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor\u2013dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes\u200853:2492\u20132500, 2004","DOI":"10.2337\/diabetes.53.9.2492"},{"key":"2022031217403281600_R111","doi-asserted-by":"crossref","unstructured":"Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both \u03b2-cell replication and neogenesis, resulting in increased \u03b2-cell mass and improved glucose tolerance in diabetic rats. Diabetes\u200848:2270\u20132276, 1999","DOI":"10.2337\/diabetes.48.12.2270"},{"key":"2022031217403281600_R112","doi-asserted-by":"crossref","unstructured":"Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem\u2008278:471\u2013478, 2003","DOI":"10.1074\/jbc.M209423200"},{"key":"2022031217403281600_R113","doi-asserted-by":"crossref","unstructured":"Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology\u2008144:5149\u20135158, 2003","DOI":"10.1210\/en.2003-0323"},{"key":"2022031217403281600_R114","doi-asserted-by":"crossref","unstructured":"Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M: Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia\u200847:806\u2013815, 2004","DOI":"10.1007\/s00125-004-1379-6"},{"key":"2022031217403281600_R115","doi-asserted-by":"crossref","unstructured":"MacLusky NJ, Cook S, Scrocchi L, Shin J, Kim J, Vaccarino F, Asa SL, Drucker DJ: Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology\u2008141:752\u2013762, 2000","DOI":"10.1210\/endo.141.2.7326"},{"key":"2022031217403281600_R116","doi-asserted-by":"crossref","unstructured":"Kinzig KP, D\u2019Alessio DA, Seeley RJ: The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci\u200822:10470\u201310476, 2002","DOI":"10.1523\/JNEUROSCI.22-23-10470.2002"},{"key":"2022031217403281600_R117","doi-asserted-by":"crossref","unstructured":"Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH: Glucagon-like peptide-1 decreases endogenous amyloid-\u03b2 peptide (A\u03b2) levels and protects hippocampal neurons from death induced by A\u03b2 and iron. J Neurosci Res\u200872:603\u2013612, 2003","DOI":"10.1002\/jnr.10611"},{"key":"2022031217403281600_R118","doi-asserted-by":"crossref","unstructured":"During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med\u20089:1173\u20131179, 2003","DOI":"10.1038\/nm919"},{"key":"2022031217403281600_R119","doi-asserted-by":"crossref","unstructured":"Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes\u200854:146\u2013151, 2005","DOI":"10.2337\/diabetes.54.1.146"},{"key":"2022031217403281600_R120","doi-asserted-by":"crossref","unstructured":"Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M: Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology\u2008144:2242\u20132252, 2003","DOI":"10.1210\/en.2003-0007"},{"key":"2022031217403281600_R121","doi-asserted-by":"crossref","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation\u2008109:962\u2013965, 2004","DOI":"10.1161\/01.CIR.0000120505.91348.58"},{"key":"2022031217403281600_R122","doi-asserted-by":"crossref","unstructured":"Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med\u20082:1254\u20131258, 1996","DOI":"10.1038\/nm1196-1254"},{"key":"2022031217403281600_R123","doi-asserted-by":"crossref","unstructured":"Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M: Exendin(9\u201339)amide is an antagonist of glucagon-like peptide-1(7\u201336)amide in humans. J Clin Invest\u2008101:1421\u20131430, 1998","DOI":"10.1172\/JCI1349"},{"key":"2022031217403281600_R124","doi-asserted-by":"crossref","unstructured":"Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9\u201339. Diabetes\u200848:86\u201393, 1999","DOI":"10.2337\/diabetes.48.1.86"},{"key":"2022031217403281600_R125","doi-asserted-by":"crossref","unstructured":"Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B: Endogenous GLP-1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 28 June 2005 [Epub ahead of print]","DOI":"10.1136\/gut.2004.059741"},{"key":"2022031217403281600_R126","doi-asserted-by":"crossref","unstructured":"Burcelin R, Da Costa A, Drucker D, Thorens B: Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide 1 receptor. Diabetes\u200850:1720\u20131728, 2001","DOI":"10.2337\/diabetes.50.8.1720"},{"key":"2022031217403281600_R127","doi-asserted-by":"crossref","unstructured":"Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC: Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch\u2008438:382\u2013387, 2001","DOI":"10.1007\/s004280000374"},{"key":"2022031217403281600_R128","doi-asserted-by":"crossref","unstructured":"Holst JJ: Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol\u2008524:263\u2013279, 2003","DOI":"10.1007\/0-306-47920-6_33"},{"key":"2022031217403281600_R129","doi-asserted-by":"crossref","unstructured":"Drucker DJ: Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology\u2008144:5145\u20135148, 2003","DOI":"10.1210\/en.2003-1147"},{"key":"2022031217403281600_R130","doi-asserted-by":"crossref","unstructured":"Drucker DJ: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs\u200812:87\u2013100, 2003","DOI":"10.1517\/13543784.12.1.87"},{"key":"2022031217403281600_R131","doi-asserted-by":"crossref","unstructured":"Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes\u200851:1461\u20131469, 2002","DOI":"10.2337\/diabetes.51.5.1461"},{"key":"2022031217403281600_R132","doi-asserted-by":"crossref","unstructured":"Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7\u201336 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia\u200842:1324\u20131331, 1999","DOI":"10.1007\/s001250051445"},{"key":"2022031217403281600_R133","doi-asserted-by":"crossref","unstructured":"Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism\u200848:385\u2013389, 1999","DOI":"10.1016\/S0026-0495(99)90090-2"},{"key":"2022031217403281600_R134","doi-asserted-by":"crossref","unstructured":"Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32\/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and \u03b2-cell glucose responsiveness in VDF (fa\/fa) Zucker rats. Diabetes\u200851:943\u2013950, 2002","DOI":"10.2337\/diabetes.51.4.943"},{"key":"2022031217403281600_R135","doi-asserted-by":"crossref","unstructured":"Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes\u200851:2677\u20132683, 2002","DOI":"10.2337\/diabetes.51.9.2677"},{"key":"2022031217403281600_R136","doi-asserted-by":"crossref","unstructured":"Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA: Dipeptidyl peptidase IV inhibitor treatment stimulates \u03b2-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes\u200852:741\u2013750, 2003","DOI":"10.2337\/diabetes.52.3.741"},{"key":"2022031217403281600_R137","doi-asserted-by":"crossref","unstructured":"Reimer MK, Holst JJ, Ahren B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol\u2008146:717\u2013727, 2002","DOI":"10.1530\/eje.0.1460717"},{"key":"2022031217403281600_R138","doi-asserted-by":"crossref","unstructured":"Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A\u200897:6874\u20136879, 2000","DOI":"10.1073\/pnas.120069197"},{"key":"2022031217403281600_R139","doi-asserted-by":"crossref","unstructured":"Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun\u2008284:501\u2013506, 2001","DOI":"10.1006\/bbrc.2001.4999"},{"key":"2022031217403281600_R140","doi-asserted-by":"crossref","unstructured":"Yasuda N, Nagakura T, Yamazaki K, Inoue T, Tanaka I: Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci\u200871:227\u2013238, 2002","DOI":"10.1016\/S0024-3205(02)01637-5"},{"key":"2022031217403281600_R141","doi-asserted-by":"crossref","unstructured":"Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A\u2008100:6825\u20136830, 2003","DOI":"10.1073\/pnas.0631828100"},{"key":"2022031217403281600_R142","doi-asserted-by":"crossref","unstructured":"Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes\u200853:1326\u20131335, 2004","DOI":"10.2337\/diabetes.53.5.1326"},{"key":"2022031217403281600_R143","doi-asserted-by":"crossref","unstructured":"Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia\u200834:52\u201354, 1991","DOI":"10.1007\/BF00404025"},{"key":"2022031217403281600_R144","unstructured":"Watschinger B, Hartter E, Traindl O, Pohanka E, Pidlich J, Kovarik J: Increased levels of plasma amylin in advanced renal failure. Clin Nephrol\u200837:131\u2013134, 1992"},{"key":"2022031217403281600_R145","doi-asserted-by":"crossref","unstructured":"Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K: Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia\u200834:129\u2013132, 1991","DOI":"10.1007\/BF00500385"},{"key":"2022031217403281600_R146","doi-asserted-by":"crossref","unstructured":"Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care\u200818:1179\u20131182, 1995","DOI":"10.2337\/diacare.18.8.1179"},{"key":"2022031217403281600_R147","doi-asserted-by":"crossref","unstructured":"Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD: Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil\u200814:123\u2013131, 2002","DOI":"10.1046\/j.1365-2982.2002.00311.x"},{"key":"2022031217403281600_R148","doi-asserted-by":"crossref","unstructured":"Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism\u200851:636\u2013641, 2002","DOI":"10.1053\/meta.2002.32022"},{"key":"2022031217403281600_R149","doi-asserted-by":"crossref","unstructured":"Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D: Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism\u200853:1227\u20131232, 2004","DOI":"10.1016\/j.metabol.2004.04.010"},{"key":"2022031217403281600_R150","doi-asserted-by":"crossref","unstructured":"Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A: Effect of 14 days\u2019 subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia\u200839:492\u2013499, 1996","DOI":"10.1007\/BF00400683"},{"key":"2022031217403281600_R151","doi-asserted-by":"crossref","unstructured":"Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A: A meta-analysis of the effect of glucagon-like peptide-1 (7\u201336) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab\u200886:4382\u20134389, 2001","DOI":"10.1210\/jcem.86.9.7877"},{"key":"2022031217403281600_R152","doi-asserted-by":"crossref","unstructured":"Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM: Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr\u200891:439\u2013446, 2004","DOI":"10.1079\/BJN20031064"},{"key":"2022031217403281600_R153","doi-asserted-by":"crossref","unstructured":"Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A: The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord\u200824:288\u2013298, 2000","DOI":"10.1038\/sj.ijo.0801126"},{"key":"2022031217403281600_R154","doi-asserted-by":"crossref","unstructured":"Harder H, Nielsen L, Tu DT, Astrup A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care\u200827:1915\u20131921, 2004","DOI":"10.2337\/diacare.27.8.1915"},{"key":"2022031217403281600_R155","doi-asserted-by":"crossref","unstructured":"Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR: Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Lond)\u200895:325\u2013329, 1998","DOI":"10.1042\/cs0950325"},{"key":"2022031217403281600_R156","doi-asserted-by":"crossref","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet\u2008359:824\u2013830, 2002","DOI":"10.1016\/S0140-6736(02)07952-7"},{"key":"2022031217403281600_R157","doi-asserted-by":"crossref","unstructured":"Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D: Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care\u200826:2835\u20132841, 2003","DOI":"10.2337\/diacare.26.10.2835"},{"key":"2022031217403281600_R158","doi-asserted-by":"crossref","unstructured":"Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem\u2008267:7402\u20137405, 1992","DOI":"10.1016\/S0021-9258(18)42531-8"},{"key":"2022031217403281600_R159","doi-asserted-by":"crossref","unstructured":"Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem\u2008272:4108\u20134115, 1997","DOI":"10.1074\/jbc.272.7.4108"},{"key":"2022031217403281600_R160","doi-asserted-by":"crossref","unstructured":"Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept\u2008117:77\u201388, 2004","DOI":"10.1016\/j.regpep.2003.10.028"},{"key":"2022031217403281600_R161","doi-asserted-by":"crossref","unstructured":"Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA: Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia\u200848:1380\u20131385, 2005","DOI":"10.1007\/s00125-005-1795-2"},{"key":"2022031217403281600_R162","doi-asserted-by":"crossref","unstructured":"Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care\u200825:1398\u20131404, 2002","DOI":"10.2337\/diacare.25.8.1398"},{"key":"2022031217403281600_R163","doi-asserted-by":"crossref","unstructured":"Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care\u200827:1335\u20131342, 2004","DOI":"10.2337\/diacare.27.6.1335"},{"key":"2022031217403281600_R164","doi-asserted-by":"crossref","unstructured":"Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1 albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes\u200852:751\u2013759, 2003","DOI":"10.2337\/diabetes.52.3.751"},{"key":"2022031217403281600_R165","doi-asserted-by":"crossref","unstructured":"Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des\u20087:1353\u20131373, 2001","DOI":"10.2174\/1381612013397357"},{"key":"2022031217403281600_R166","doi-asserted-by":"crossref","unstructured":"Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia\u200848:838\u2013848, 2005","DOI":"10.1007\/s00125-005-1732-4"},{"key":"2022031217403281600_R167","doi-asserted-by":"crossref","unstructured":"Thompson RG, Pearson L, Kolterman OG: Effects of 4 weeks\u2019 administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia\u200840:1278\u20131285, 1997","DOI":"10.1007\/s001250050821"},{"key":"2022031217403281600_R168","doi-asserted-by":"crossref","unstructured":"Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes\u200846:632\u2013636, 1997","DOI":"10.2337\/diabetes.46.4.632"},{"key":"2022031217403281600_R169","doi-asserted-by":"crossref","unstructured":"Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin: the Pramlintide in Type 2 Diabetes Group. Diabetes Care\u200821:987\u2013993, 1998","DOI":"10.2337\/diacare.21.6.987"},{"key":"2022031217403281600_R170","doi-asserted-by":"crossref","unstructured":"Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care\u200825:724\u2013730, 2002","DOI":"10.2337\/diacare.25.4.724"},{"key":"2022031217403281600_R171","doi-asserted-by":"crossref","unstructured":"Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med\u200821:1204\u20131212, 2004","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"2022031217403281600_R172","doi-asserted-by":"crossref","unstructured":"Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther\u20084:51\u201361, 2002","DOI":"10.1089\/15209150252924094"},{"key":"2022031217403281600_R173","doi-asserted-by":"crossref","unstructured":"Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care\u200826:784\u2013790, 2003","DOI":"10.2337\/diacare.26.3.784"},{"key":"2022031217403281600_R174","doi-asserted-by":"crossref","unstructured":"Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care\u200826:3074\u20133079, 2003","DOI":"10.2337\/diacare.26.11.3074"},{"key":"2022031217403281600_R175","doi-asserted-by":"crossref","unstructured":"Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther\u20087:467\u2013477, 2005","DOI":"10.1089\/dia.2005.7.467"},{"key":"2022031217403281600_R176","doi-asserted-by":"crossref","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care\u200828:1092\u20131100, 2005","DOI":"10.2337\/diacare.28.5.1092"},{"key":"2022031217403281600_R177","doi-asserted-by":"crossref","unstructured":"Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care\u200827:2628\u20132635, 2004","DOI":"10.2337\/diacare.27.11.2628"},{"key":"2022031217403281600_R178","doi-asserted-by":"crossref","unstructured":"Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care\u200828:1083\u20131091, 2005","DOI":"10.2337\/diacare.28.5.1083"},{"key":"2022031217403281600_R179","doi-asserted-by":"crossref","unstructured":"Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med\u2008143:559\u2013569, 2005","DOI":"10.7326\/0003-4819-143-8-200510180-00006"},{"key":"2022031217403281600_R180","doi-asserted-by":"crossref","unstructured":"Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and \u03b1- and \u03b2-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes\u200853:1187\u20131194, 2004","DOI":"10.2337\/diabetes.53.5.1187"},{"key":"2022031217403281600_R181","doi-asserted-by":"crossref","unstructured":"Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care\u200827:2874\u20132880, 2004","DOI":"10.2337\/diacare.27.12.2874"},{"key":"2022031217403281600_R182","doi-asserted-by":"crossref","unstructured":"Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab\u200889:2078\u20132084, 2004","DOI":"10.1210\/jc.2003-031907"},{"key":"2022031217403281600_R183","doi-asserted-by":"crossref","unstructured":"Ahren B, Pacini G, Foley JE, Schweizer A: Improved meal-related \u03b2-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care\u200828:1936\u20131940, 2005","DOI":"10.2337\/diacare.28.8.1936"},{"key":"2022031217403281600_R184","doi-asserted-by":"crossref","unstructured":"Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed \u03b2-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab\u200890:4888\u20134994, 2005","DOI":"10.1210\/jc.2004-2460"},{"key":"2022031217403281600_R185","doi-asserted-by":"crossref","unstructured":"Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB: Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia\u200848:2236\u20132240, 2005","DOI":"10.1007\/s00125-005-1933-x"},{"key":"2022031217403281600_R186","doi-asserted-by":"crossref","unstructured":"Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV: Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med\u2008353:249\u2013254, 2005","DOI":"10.1056\/NEJMoa043690"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/29\/2\/435\/594205\/zdc00206000435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/29\/2\/435\/594205\/zdc00206000435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T18:34:41Z","timestamp":1647110081000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/29\/2\/435\/26464\/Emerging-Therapies-Mimicking-the-Effects-of-Amylin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":186,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.29.02.06.dc05-1267","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}